Turbine joins Multimodal AI-ready data collaboration to train Virtual Assays in immune biology
Read more

Publications

Modeling ADC payload biology using Simulated Cells 
Poster

Ákos Tarcsay, István Taisz, Boldizsár Elek, Gábor Bereczki, Ágoston Mihalik, Bálint Farkas, Dániel Veres

ADCs represent a new era of targeted cancer therapy with 15 approved drugs. However, over 100 discontinued ADC programs and a similar number of active clinical trials highlight the difficulties of identifying the optimal combination of antibody, target, payload, linker, drug-antibody ratio and indication. Understanding mechanisms and factors contributing to different levels… read more

System level network data and models attack cancer drug resistance 
Publication

Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely

Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small-scale interactomes and signalling network models of drug resistance guide directed drug development. Recently, proteome-wide human interactome and signalling network data have become available, which have been extended by… read more

Cancer drug resistance as learning of signaling networks 
Poster

Dávid Keresztes, Márk Kerestély, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely

Drug resistance is a major cause of tumor mortality. Signaling networks became useful tools for driving pharmacological interventions against cancer drug resistance. Signaling datasets now cover the entire human cell. Recently, network adaptation became understood as a learning process. We review rapidly increasing evidence showing that the development of cancer drug resistance… read more

Identification and prospective validation of synergistic drug combinations using high throughput <i>in silico</i> simulations of cancer cell avatars 
Poster

Hasan Mamar, Orsolya Papp, Iván Fekete, Boldizsár Elek, Dániel V. Veres

Small-molecule drug combinations promise durable efficacy and improved patient survival across cancer indications while managing toxicity by decreasing the dosages of individual combination partners. However, finding synergistic combination partners while retaining a safe therapeutic window remains a major challenge limited by preclinical experimental capabilities not addressing the complexity of combining hundreds of… read more

New technologies to accelerate ADC design 
Webinar

Dániel Veres, Hassan Naseri, Eleni Tokali

ADCs represent a new era in targeted cancer therapy, with 15 approved drugs currently on the market. However, more than 100 discontinued programs and a similar number of active clinical trials also underscore the challenges in ADC design. Gaining a deeper understanding of the mechanisms and factors contributing to ADC efficacy and… read more

Modeling ADC payload biology using network based avatars 
Poster

István Taisz, Elek Boldizsár, Szilvia Barsi, Zsolt Gyure, Ágoston Mihalik, Dániel Veres, Ákos Tarcsay

ADCs represent a new era of targeted cancer therapy with 15 approved drugs. However, over 100 discontinued ADC programs and similar number of active clinical trials highlight the difficulties of identifying the optimal combination of antibody, target, payload, linker, drug-antibody-ratio and indication. read more